{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:05:45Z","timestamp":1794661545446,"version":"4.9.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed\/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]\u2013targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)\u2013positron emission tomography (PET)\/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET\/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET\/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of \u226525\u00a0cm3 at baseline [18F]FDG-PET\/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET\/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014360","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:53:26Z","timestamp":1732730006000},"page":"571-582","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Clinical impact of [18F]FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"In\u00e9s","family":"Zugasti","sequence":"first","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-063X","authenticated-orcid":false,"given":"Marta","family":"Tormo-Ratera","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-5420","authenticated-orcid":false,"given":"Aina","family":"Oliver-Cald\u00e9s","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"},{"name":"2Hospital Universitari Son Espases, Fundaci\u00f3 Institut d'Investigaci\u00f3 Sanit\u00e0ria Illes Balears, Palma de Mallorca, Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2552-3903","authenticated-orcid":false,"given":"Juan Carlos","family":"Soler-Perromat","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-6707","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[{"name":"3Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Instituto Universitario de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Universidad de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1752-3081","authenticated-orcid":false,"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-2549","authenticated-orcid":false,"given":"Valent\u00edn","family":"Caba\u00f1as","sequence":"additional","affiliation":[{"name":"4Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB Pascual Parrilla, Universidad de Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"5Hospital Universitario 12 de Octubre, Complutense University, i+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-0007","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Bartolom\u00e9-Solanas","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-2276","authenticated-orcid":false,"given":"Marta","family":"Espa\u00f1ol-Rego","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6408-1747","authenticated-orcid":false,"given":"Juan Luis","family":"Reguera-Ortega","sequence":"additional","affiliation":[{"name":"6Hospital Universitario Virgen del Roc\u00edo, Instituto de Biomedicina de Sevilla (CIBERONC), Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[{"name":"3Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Instituto Universitario de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Universidad de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Alvarez Perez","sequence":"additional","affiliation":[{"name":"6Hospital Universitario Virgen del Roc\u00edo, Instituto de Biomedicina de Sevilla (CIBERONC), Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0002-6492","authenticated-orcid":false,"given":"Sara","family":"Varea","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-9964","authenticated-orcid":false,"given":"Eul\u00e0lia","family":"Olesti","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Gomez-Grande","sequence":"additional","affiliation":[{"name":"5Hospital Universitario 12 de Octubre, Complutense University, i+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Frutos","sequence":"additional","affiliation":[{"name":"4Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB Pascual Parrilla, Universidad de Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-514X","authenticated-orcid":false,"given":"Pilar","family":"Tamayo","sequence":"additional","affiliation":[{"name":"3Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Instituto Universitario de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Universidad de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3064-1648","authenticated-orcid":false,"given":"Manel","family":"Juan","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-1466","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Moraleda","sequence":"additional","affiliation":[{"name":"4Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, IMIB Pascual Parrilla, Universidad de Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Azucena","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"5Hospital Universitario 12 de Octubre, Complutense University, i+12, Centro Nacional de Investigaciones Oncol\u00f3gicas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"3Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Instituto Universitario de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Universidad de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2189-8721","authenticated-orcid":false,"given":"Xavier","family":"Tom\u00e1s","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Setoain","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"},{"name":"7Biomedical Imaging Group, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[{"name":"1Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"9","key":"2025032119364231500_bib1","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"2025032119364231500_bib2","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025032119364231500_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025032119364231500_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10297","key":"2025032119364231500_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2025032119364231500_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032119364231500_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2025032119364231500_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025032119364231500_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025032119364231500_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00330-007-0738-3","article-title":"Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma","volume":"18","author":"Kr\u00f6pil","year":"2008","journal-title":"Eur Radiol"},{"issue":"1","key":"2025032119364231500_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2025032119364231500_bib12","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ejrad.2014.02.008","article-title":"Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease","volume":"83","author":"Wolf","year":"2014","journal-title":"Eur J Radiol"},{"issue":"2","key":"2025032119364231500_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejrad.2004.04.015","article-title":"Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography","volume":"54","author":"Horger","year":"2005","journal-title":"Eur J Radiol"},{"issue":"11","key":"2025032119364231500_bib14","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","article-title":"European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when","volume":"103","author":"Caers","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"2025032119364231500_bib15","first-page":"998","article-title":"Multiple myeloma guidelines and their recent updates: implications for imaging","volume":"191","author":"Mosebach","year":"2019","journal-title":"R\u00f6fo"},{"key":"2025032119364231500_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.02.012","article-title":"Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography\/CT (18F-FDG PET\/CT) in patients with myeloma: systematic review of diagnostic performance","volume":"124","author":"Gariani","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2025032119364231500_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"2025032119364231500_bib18","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18 F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025032119364231500_bib19","first-page":"479","article-title":"Application of 18 F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"2","key":"2025032119364231500_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00330-012-2600-5","article-title":"Comparative diagnostic performance of 18F-FDG PET\/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation","volume":"23","author":"Derlin","year":"2013","journal-title":"Eur Radiol"},{"issue":"1","key":"2025032119364231500_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00277-019-03852-2","article-title":"Visual and volumetric parameters by 18F-FDG-PET\/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma","volume":"99","author":"Fonti","year":"2020","journal-title":"Ann Hematol"},{"issue":"10","key":"2025032119364231500_bib22","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","article-title":"Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma","volume":"30","author":"Oliver-Caldes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025032119364231500_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18 F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncology"},{"issue":"5","key":"2025032119364231500_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025032119364231500_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor t cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Tansplant Cell Ther"},{"issue":"18","key":"2025032119364231500_bib26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med Overseas Ed"},{"issue":"7","key":"2025032119364231500_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2025032119364231500_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"issue":"28","key":"2025032119364231500_bib29","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2025032119364231500_bib30","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.18632\/oncotarget.2290","article-title":"18 FDG-PET\/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation","volume":"5","author":"Lapa","year":"2014","journal-title":"Oncotarget"},{"issue":"10","key":"2025032119364231500_bib31","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2025032119364231500_bib32","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","article-title":"Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma","volume":"53","author":"Fonti","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"23","key":"2025032119364231500_bib33","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2025032119364231500_bib34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","article-title":"Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma","volume":"38","author":"Haznedar","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"2025032119364231500_bib35","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025032119364231500_bib36","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","article-title":"The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation","volume":"21","author":"Patriarca","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025032119364231500_bib37","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025032119364231500_bib40","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"2025032119364231500_bib41","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"issue":"16 suppl","key":"2025032119364231500_bib42","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/571\/2353912\/blooda_adv-2024-014360-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/571\/2353912\/blooda_adv-2024-014360-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:00:14Z","timestamp":1742587214000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/571\/526314\/Clinical-impact-of-18F-FDG-PET-CT-in-ARI0002h"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014360","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}